April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Conjuntival Immunocytochemical Analysis Prior and After Treatment With Osmoprotective Lubricant in Patients With Dysfunctional Tear Syndrome
Author Affiliations & Notes
  • J. L. Covre
    Ophthalmology, UNIFESP, S.P, Brazil
  • R. M. Hazarbassanov
    Ophthalmology, UNIFESP, S.P, Brazil
  • R. R. Loureiro
    Ophthalmology, UNIFESP, S.P, Brazil
  • P. C. Cristovam
    Ophthalmology, UNIFESP, S.P, Brazil
  • J. Barros
    Ophthalmology, UNIFESP, S.P, Brazil
  • D. de Freitas
    Ophthalmology, UNIFESP, S.P, Brazil
  • A. Hofling Lima
    Ophthalmology, UNIFESP, S.P, Brazil
  • M. Campos
    Ophthalmology, UNIFESP, S.P, Brazil
  • J. A. P. Gomes
    Ophthalmology, UNIFESP, S.P, Brazil
  • Footnotes
    Commercial Relationships  J.L. Covre, None; R.M. Hazarbassanov, None; R.R. Loureiro, None; P.C. Cristovam, None; J. Barros, None; D. de Freitas, None; A. Hofling Lima, None; M. Campos, None; J.A.P. Gomes, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 6286. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. L. Covre, R. M. Hazarbassanov, R. R. Loureiro, P. C. Cristovam, J. Barros, D. de Freitas, A. Hofling Lima, M. Campos, J. A. P. Gomes; Conjuntival Immunocytochemical Analysis Prior and After Treatment With Osmoprotective Lubricant in Patients With Dysfunctional Tear Syndrome. Invest. Ophthalmol. Vis. Sci. 2010;51(13):6286.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Evaluate immunostaining patterns of inflammation and osmoprotection markers prior and after treatment with osmoprotective lubricant compared to non-osmoprotective, on patients with evaporative dysfunctional tear syndrome (EDTS).

Methods: : 35 patients were enrolled in this study. They were divided into group (A), 15 patients with EDTS, and (B) 20 patients without EDTS who underwent LASIK (10) or PRK (10). In group A, 10 patients were treated with Optive, as 4 patients from group B/PRK and 6 patients from group B/LASIK. Additionally to diagnostic exams, impression cytology (IC) was performed on all patients. IC conjunctival samples were submitted to immunocytochemistry (ICC) for inflammation marker human leukocyte antigen-DR (HLA-DR) and L-carnitine, Optive®’s osmoprotective component.

Results: : All exams pre-treatment were performed to this moment. ICC of conjunctiva samples showed 42.86% positivity for HLA-DR on group A and 20% for group B/LASIK, 30% for PRK, before treatment (p=0.4896, Χ2 test).ICC for L-carnitine staining was 53.33% positive for A, 22% for LASIK and 10% for PRK subgroup, before treatment (p=0.0572, Χ2 test).

Conclusions: : Conjunctival cells have shown a tendency of higher expression of inflammation marker HLA-DR on EDTS patients, and, interestingly, L-carnitine as well. To our knowledge, this is the first report of L-carnitine staining on conjuntival samples from EDTS patients, prior treatment. Both markers could be used as diagnostic tools for early EDTS outset and prognosis.

Keywords: cornea: tears/tear film/dry eye 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.